- Home
- SPGC vs CHRO Comparison
SPGC vs CHRO Comparison
Compare SPGC & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPGC
- CHRO
- Stock Information
- Founded
- SPGC 2018
- CHRO 2002
- Country
- SPGC United States
- CHRO United States
- Employees
- SPGC N/A
- CHRO N/A
- Industry
- SPGC
- CHRO
- Sector
- SPGC
- CHRO
- Exchange
- SPGC Nasdaq
- CHRO Nasdaq
- Market Cap
- SPGC 3.3M
- CHRO 3.8M
- IPO Year
- SPGC 2023
- CHRO 2024
- Fundamental
- Price
- SPGC $0.29
- CHRO $1.90
- Analyst Decision
- SPGC
- CHRO Strong Buy
- Analyst Count
- SPGC 0
- CHRO 1
- Target Price
- SPGC N/A
- CHRO N/A
- AVG Volume (30 Days)
- SPGC 1.9M
- CHRO 855.2K
- Earning Date
- SPGC 03-17-2025
- CHRO 02-20-2025
- Dividend Yield
- SPGC N/A
- CHRO N/A
- EPS Growth
- SPGC N/A
- CHRO N/A
- EPS
- SPGC N/A
- CHRO N/A
- Revenue
- SPGC $2,491,000.00
- CHRO N/A
- Revenue This Year
- SPGC $899.43
- CHRO N/A
- Revenue Next Year
- SPGC $49.83
- CHRO N/A
- P/E Ratio
- SPGC N/A
- CHRO N/A
- Revenue Growth
- SPGC 840.00
- CHRO N/A
- 52 Week Low
- SPGC $0.26
- CHRO $0.45
- 52 Week High
- SPGC $9.17
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- SPGC 27.10
- CHRO 86.63
- Support Level
- SPGC $0.28
- CHRO $0.81
- Resistance Level
- SPGC $0.32
- CHRO $1.10
- Average True Range (ATR)
- SPGC 0.07
- CHRO 0.26
- MACD
- SPGC 0.04
- CHRO 0.08
- Stochastic Oscillator
- SPGC 3.07
- CHRO 70.64
About SPGC Sacks Parente Golf Inc.
Sacks Parente Golf Inc is a technology-forward golf company, with a growing portfolio of golf products, including putting instruments, golf shafts, golf grips, and other golf-related products. It designs, manufactures, and sells technology-forward, golf equipment, which is comprised of putting instruments, golf shafts, golf grips, and related product groups. It designs its golf products to fit golfers of all skill levels, amateur and professional. Its business segments currently include, golf putting instruments, golf shafts, and golf related products.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.